Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015

Transfusion

Volumn 57, Issue , 2017, Pages 1599-1624

  Sapiano, Mathew R P ^a   Savinkina, Alexandra A ^a,b   Ellingson, Katherine D ^a,c   Haass, Kathryn A ^a   Baker, Misha L ^a,d   Henry, Richard A ^e   Berger, James J ^e   Kuehnert, Matthew J ^a   Basavaraju, Sridhar V ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d NORTHROP GRUMMAN CORPORATION   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIGEN;

APHERESIS; ARTICLE; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; ERYTHROCYTE; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITAL POLICY; HUMAN; INTENSIVE CARE; PEDIATRICS; PLASMA TRANSFUSION; RECIPIENT; THROMBOCYTOPENIA; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

BLOOD DONORS; BLOOD SPECIMEN COLLECTION; ERYTHROCYTES; HUMANS; SURVEYS AND QUESTIONNAIRES;

EID: 85020250425     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14168     Document Type: Article

References (50)

1. Chung KW, Basavaraju SV, Mu Y, et al. Declining blood collection and utilization in the United States. Transfusion 2016;56:2184-92.
2. Ellingson KD, Sapiano MRP, Haass KA, et al. Continued Decline in Blood Collection and Transfusion in the United States – 2015; Transfusion. 2017. (In Press).
3. Sullivan MT, McCullough J, Schreiber GB, et al. Blood collection and transfusion in the United States in 1997. Transfusion 2002;42:1253-60.
4. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion 2005;45:141-8.
5. Sullivan MT, Cotten R, Read EJ, et al. Blood collection and transfusion in the United States in 2001. Transfusion 2007;47:385-94.
6. The 2011 National Blood Collection and Utilization Survey Report. Washington (DC): US Department of Health and Human Services; 2013.
7. Recommendations of the 48th ACBTSA Meeting, November 28-29, 2015. Washington (DC): U.S. Department of Health and Human Services; 2015.
8. U.S. FoodBlood establishment registration and product listing [Internet]. Silver Spring (MD): and Drug Administration; 2017 [cited 2017 Feb 27]. Available from: https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/EstablishmentRegistration/BloodEstablishmentRegistration/default.htm.
9. He Y. Raghunathan Tukey's gh distribution for multiple imputation. Am Stat Assoc 2006;60:251-6.
10. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken (NJ): Wiley; 2004.
11. Woodruff R. A simple method for approximating the variance of a complicated estimate. J Am Stat Assoc 1971;66:411-4.
12. Vajpayee N, Graham SS, Bem S. Basic examination of blood and bone marrow. In: McPherson RA, Pincus M, editors. Henry's clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia (PA): Elsevier Saunders; 2011.
13. Prothrombin time test [Internet]. Rochester (MN): Mayo Clinic; c1998-2017 [cited January 16, 2017]. Available from: http://www.mayoclinic.org/tests-procedures/prothrombin-time/details/results/rsc-20163828.
14. Normal lab values [Internet]. San Francisco: University of California San Francisco; yyyy [cited January 16, 2017]. Available from: http://missinglink.ucsf.edu/lm/ids_106_lowergi/lower%20gi/mainpages/normallabvalues.htm.
15. Schmaier AH. Laboratory evaluation of hemostatic and thrombotic disorders. In: Hoffman R, Benz EJ, Silberstein LE, et al. editors. Hematology: basic principles and practice. Chapter 131, 6th ed. Philadelphia (PA): Elsevier Saunders; 2012.
16. Goodnough LT. Blood management: transfusion medicine comes of age. Lancet 2013;381:1791-2.
17. Stokes EA, Wordsworth S, Bargo D, et al. Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial. BMJ Open 2016;6:e011311.
18. Xydas S, Magovern CJ, Slater JP, et al. Implementation of a comprehensive blood conservation program can reduce blood use in a community cardiac surgery program. J Thorac Cardiovasc Surg 2012;143:926-35.
19. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997;277:967-72.
20. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000;284:229-35.
21. Zou S, Musavi F, Notari EP 4th, et al. Changing age distribution of the blood donor population in the United States. Transfusion 2008;48:251-7.
22. Schreiber GB, Sharma UK, Wright DJ, et al. First year donation patterns predict long-term commitment for first-time donors. Vox Sang 2005;88:114-21.
23. Trouern-Trend JJ, Cable RG, Badon SJ, et al. A case-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 1999;39:316-20.
24. Eder AF, Hillyer CD, Dy BA, et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA 2008;299:2279-86.
25. Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. JAMA 1981;245:2038-43.
26. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2011;51:511-22.
27. Blood Products Advisory Committee. Topic IA. Considerations for iron management in blood donors. Silver Spring (MD): U.S. Food and Drug Administration; 2016.
28. Notari EP, Zou S, Fang CT, et al. Age-related donor return patterns among first-time blood donors in the United States. Transfusion 2009;49:2229-36.
29. Blood Products Advisory Committee. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Silver Spring (MD): U.S. Food and Drug Administration; 2016.
30. Toner RW, Pizzi L, Leas B, et al. Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy 2011;9:29-37.
31. Mulcahy A, Kapinos K, Briscombe B, et al. Towards a sustainable blood supply in the United States. Santa Monica (CA): RAND Corporation; 2016.
32. Fatalities reported to FDA following blood collection and transfusion (FY2015) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration, Center for Biologics Evaluation and Research; 2015 [cited January 16, 2017]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM518148.pdf.
33. National Healthcare Safety Network biovigilance component hemovigilance module surveillance protocol [Internet]. Atlanta: Centers for Disease Control and Prevention; 2017 [cited 2017 Jan 30]. Available from: https://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf.
34. Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997;46:1-55. [9148133]
35. Ertel SH, Nelson RS, Cartter ML. Effect of surveillance method on reported characteristics of Lyme disease, Connecticut, 1996-2007. Emerg Infect Dis 2012;18:242-7.
36. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004;44:1774-89.
37. International Society of Blood Transfusion Working Party on Haemovigilance. Transfusion-associated circulatory overload (TACO): draft revised reporting criteria [Internet]. Bethesda: AABB; 2016 [cited 2017 Jan 31]. Available from: https://www.aabb.org/research/hemovigilance/Documents/TACO-reporting-criteria-draft-Nov-2016.pdf.
38. Badami KG, Joliffe E, Stephens M. Transfusion-associated dyspnea--shadow or substance? Vox Sang 2015;109:197-200.
39. Harvey AR, Basavaraju SV, Chung KW, et al. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 2015;55:709-18.
40. Basavaraju SV, Haass KA, Sapiano MRP, Kuehnert MJ. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2013 to 2015. ISBT Conference Abstract; 2016.
41. Kasprisin DO, Glynn SH, Taylor F, et al. Moderate and severe reactions in blood donors. Transfusion 1992;32:23-6.
42. Newman BH, Newman DT, Ahmad R, et al. The effect of whole-blood donor adverse events on blood donor return rates. Transfusion 2006;46:1374-9.
43. Eder AF, Dy BA, Kennedy JM, et al. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008;48:1809-19.
44. Goldman M, Land K, Robillard P, et al. Development of standard definitions for surveillance of complications related to blood donation. Vox Sang 2016;110:185-8.
45. AABB donor hemovigilance report [Internet]. Bethesda: AABB; 2012 [cited January 8, 2017]. Available from: http://www.aabb.org/research/hemovigilance/Documents/aabb-donor-hemovigilance-report-2012.pdf.
46. DonorHART donor hemovigilance analysis & reporting tool: user manual 2.0 [Internet]. Bethesda: AABB; 2014 [cited January 8, 2017]. http://www.aabb.org/research/hemovigilance/Documents/biovigilancemanual.pdf.
47. Rajbhandary S, Stubs JR, Land KJ, et al. AABB donor hemovigilance report: 2012-2014 on behalf of the AABB US Donor Hemovigilance Working Group. Bethesda: AABB; 2016.
48. Hillyer CD, Shaz BH, Winkler AM, et al. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev 2008;22:117-32.
49. Liu Z, Liu M, Mercado T, et al. Extended blood group molecular typing and next-generation sequencing. Transfus Med Rev 2014;28:177-86.
50. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of PLTs for transfusion. Silver Spring (MD): US Food and Drug Administration, Center for Biologics Evaluation and Research; 2016.